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Abstract
Background: Despite the clinical significance of muscle pain, and the extensive investigation of the
properties of muscle afferent fibers, there has been little study of the ion channels on sensory
neurons that innervate muscle. In this study, we have fluorescently tagged sensory neurons that
innervate the masseter muscle, which is unique because cell bodies for its muscle spindles are in a
brainstem nucleus (mesencephalic nucleus of the 5th cranial nerve, MeV) while all its other sensory
afferents are in the trigeminal ganglion (TG). We examine the hypothesis that certain molecules
proposed to be used selectively by nociceptors fail to express on muscle spindles afferents but
appear on other afferents from the same muscle.
Results: MeV muscle afferents perfectly fit expectations of cells with a non-nociceptive sensory
modality: Opiates failed to inhibit calcium channel currents (ICa) in 90% of MeV neurons, although
ICa were inhibited by GABAB receptor activation. All MeV afferents had brief (1 msec) action
potentials driven solely by tetrodotoxin (TTX)-sensitive Na channels and no MeV afferent
expressed either of three ion channels (TRPV1, P2X3, and ASIC3) thought to be transducers for
nociceptive stimuli, although they did express other ATP and acid-sensing channels. Trigeminal
masseter afferents were much more diverse. Virtually all of them expressed at least one, and often
several, of the three putative nociceptive transducer channels, but the mix varied from cell to cell.
Calcium currents in 80% of the neurons were measurably inhibited by µ-opioids, but the extent of
inhibition varied greatly. Almost all TG masseter afferents expressed some TTX-insensitive sodium
currents, but the amount compared to TTX sensitive sodium current varied, as did the duration of
action potentials.
Conclusion:  Most masseter muscle afferents that are not muscle spindle afferents express
molecules that are considered characteristic of nociceptors, but these putative muscle nociceptors
are molecularly diverse. This heterogeneity may reflect the mixture of metabosensitive afferents
which can also signal noxious stimuli and purely nociceptive afferents characteristic of muscle.
Background
The masseter muscle is involved in many painful condi-
tions which are grouped under the general heading of
temporomandibular disorders [1]. Although a role of
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primary afferents innervating the masseter muscle in the
development and maintenance of some of these pain
states has been generally accepted, the cellular properties
of masseter afferents have not been extensively investi-
gated [2]. The trigeminal sensory system is unusual
because the cell bodies of the trigeminal primary afferent
neurons are located both in the trigeminal ganglion (TG)
and in the mesencephalic nucleus of the 5th cranial nerve
(MeV) in the brainstem. The proprioceptive afferents
located in the MeV include those arising from the mas-
seter muscle [3], and this unique anatomical segregation
enables direct comparison of the expression of proteins
involved sensory transduction and its modulation
between proprioceptive and other muscle afferents.
We have previously compared the types of P2X receptor
and acid gated ion channel (ASIC)-mediated response
between nociceptive and non-nociceptive sensory affer-
ents [4,5], utilizing the MeV proprioceptors as the non-
nociceptive neuronal population and either tooth pulp or
cardiac afferents as the exemplar nociceptors. However,
we have not previously compared the properties of differ-
ent types of sensory afferent innervating the same tissue.
We hypothesize that afferents from the masseter muscle
that have different sensory functions will have different
complements of signal detection and transduction mole-
cules from each other, and that these different molecular
profiles in part determine the response properties of the
neurons to sensory stimuli. to In this study we have inves-
tigated the expression of sensory transduction-related ion
channels and modulatory receptors in masseter afferent
neurons located in the TG, which presumably represent a
population of sensory neurons with mixed sensory
modalities, and the proprioceptive masseter afferents
located in the MeV. We determined the responses of these
cell populations to the sensory mediators ATP, capsaicin
and acid and potential analgesic agents such as µ-opioid
agonists and baclofen [6,7]. There were significant differ-
ences between TG masseter afferents and MeV afferents in
their voltage-gated sodium current (INa) expression,
responses to sensory mediators and µ opioid agonists.
Results
We made recordings from 143 TG neurons and 31 brain-
stem MeV neurons labeled by injection of DiI into the
masseter muscle. The diameter of the labeled ganglion
cells ranged between 13 µm and 50 µm, the diameter of
the cells isolated from the MeV nucleus ranged between
29 µm and 60 µm. We also recorded currents from 70
unlabeled TG neurons, with diameters between 12 µm
and 50 µm.
Action Potentials and Sodium Currents
Action potentials in masseter afferent neurons were exam-
ined in whole cell current clamp recordings (Figure 1).
Neurons were held at -70 mV and sufficient current
injected (0.5–3 ms duration) to elicit an action potential.
Action potential duration was measured at 0 mV. Action
potentials elicited from masseter afferents isolated from
the TG varied considerably in width, with durations
between 0.6 ms and 5.2 ms at 0 mV (average duration 2.2
± 0.2 ms, n = 27, Figure 1B). By contrast, MeV masseter
afferent action potentials were narrower and displayed
much less variability with a mean AP duration of 0.8 ±
0.05 ms (range 0.6 ms to 1.1 ms, n = 13, Figure 1B).
The types of voltage-dependent sodium channel currents
(INa) contributing to the action potentials in masseter
afferents were examined using conventional voltage
clamp recordings made in low extracellular Na (20 mM or
40 mM) in order to minimize the size of evoked INa. The
peak INa was determined by stepping the neurons from a
holding potential of -90 mV to potentials between -100
mV and +45 mV. Even in conditions of reduced external
Na, the peak amplitude of evoked currents was substan-
tial; peak INa averaged 11 ± 3 nA in ganglion afferents (n =
27) and 22 ± 4 nA in masseter afferents isolated from the
MeV nucleus (n = 15). Application of tetrodotoxin (TTX,
300 nM), a potent inhibitor of many types of INa, inhib-
ited the peak INa in ganglion masseter afferents in a highly
variable manner (Figure 2). The average inhibition by TTX
was 38 ± 6% (n = 27) but the inhibition ranged in individ-
ual cells from nothing to 100%. In contrast, TTX com-
pletely inhibited the peak INa in masseter afferents isolated
from the MeV nucleus (99 ± 1%, n = 15, Figure 2).
Modulation of ICa
The calcium channel current (ICa) density of neurons was
determined by repetitively stepping the membrane poten-
tial from a holding potential of -90 mV to test potentials
between -60 and +60 mV. The ICa density of masseter affer-
ents was similar to that of unlabeled cells (115 ± 6 pA/pF,
n = 104 vs 109 ± 9 pA/pF, n = 53). The calcium channel
density of masseter afferents isolated from the MeV
nucleus was 36 ± 8 pA/pF (n = 12).
The sensitivity of the masseter afferents to opioids was
determined by examining the modulation of ICa by ago-
nists selective for µ-, δ- and κ-opioid receptors and the
nociceptin receptor ORL1 (Figure 3). Cells were consid-
ered responsive if there was a reversible inhibition of the
ICa evoked by step from -90 mV to 0 mV of at least 10%.
Maximally effective concentrations of the µ-opioid ago-
nist DAMGO (3 µM–10 µM, [8]) inhibited ICa in 74 of 92
labeled TG neurons (80%), and in 29 of 49 unlabeled
neurons assessed at the same time (59%; P < 0.01, χ 2). In
responsive masseter afferents DAMGO (3–10 µM) inhib-
ited ICa by 46 ± 3%, in responsive unlabeled cells the inhi-
bition of ICa was 39 ± 4%. We have previously arbitrarily
divided trigeminal neurons into small (diameter <30Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
Page 3 of 13
(page number not for citation purposes)
µm), intermediate (diameter between 30 µm–40 µm) and
large (diameter >40 µm) cells [8]. DAMGO inhibited ICa
in 85% of small masseter afferents, in 73% of intermedi-
ate diameter cells and in 82% of large cells (Figure 3C).
The inhibition of ICa by DAMGO was 48 ± 4% in small
masseter afferents, 50 ± 4% in intermediate cells and 36 ±
4% in large masseter afferents. Neither the κ-opioid ago-
nist U69-593 (3 µM, n = 10) or the δ-opioid agonist del-
Contrasting action potential characteristics of masseter muscle sensory afferents Figure 1
Contrasting action potential characteristics of masseter muscle sensory afferents. Action potentials were elicited 
by injecting a brief depolarizing current step to neurons held at -70 mV and the width measured at 0 mV. A(i) illustrates 2 
example action potentials from trigeminal ganglion masseter afferents while A(ii) illustrates an action potential from a typical 
MeV nucleus masseter afferent. Action potentials widths are plotted against cell body diameter in B, note the wide range of 
action potentials widths in masseter afferents isolated from the trigeminal ganglion contrasting with the very tightly grouped 
action potentials widths from MeV masseter afferents.Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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Contrasting sodium currents in masseter afferents Figure 2
Contrasting sodium currents in masseter afferents. MeV masseter afferents express only TTX-sensitive INa, but trigem-
inal ganglion masseter afferents display great variation in the proportion of TTX-sensitive to TTX-resistant INa among cells. INa 
were elicited by voltage steps from a holding potential of -90 mV, as diagrammed next to each set of traces. TTX-sensitive INa 
were obtained by digitally subtracting the INa remaining in TTX (300 nM) from the total INa. A trigeminal ganglion masseter 
afferent is illustrated in A; (i) illustrates the TTX-sensitive and TTX-resistant INa at -20 mV, a potential where TTX-sensitive 
current predominates while (ii) shows the total INa and TTX-insensitive INa at the potential where TTX-sensitive INa is maximal. 
The peak amplitudes of the total INa, TTX-sensitive and -resistant INa are plotted in (iii). A typical MeV masseter afferent is illus-
trated in B, (i) illustrates the INa and TTX-insensitive inward current at the test potential where INa is maximal; (ii) shows the 
TTX-sensitive INa over a range of test potentials. The peak amplitudes of the total INa, TTX-sensitive and residual current (ICa, 
see Table 1) are plotted in (iii). C) Illustrates the proportion of the peak inward current in TG and MeV masseter afferents that 
was sensitive to TTX (300 nM). The proportion of TTX-sensitive INa for the cell illustrated in A) would be calculated at a test 
potential of +5 mV.Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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Contrasting opioid modulation of masseter afferent ICa Figure 3
Contrasting opioid modulation of masseter afferent ICa. ICa were elicited by stepping from a holding potential of -90 mV 
to test potential of 0 mV. A) (i) Example ICa traces from a trigeminal ganglion masseter afferent recorded in control conditions 
and in the presence of the µ-opioid agonist DAMGO and the GABA-B receptor agonist baclofen. (ii) A timeplot of the ICa 
amplitude at 0 mV for the cell illustrated in (i). Drugs were applied for the duration of the bars. B) (i) Example ICa traces from a 
MeV masseter afferent recorded in control conditions and in the presence of the µ-opioid agonist DAMGO the GABA-B 
receptor agonist baclofen and the ICa blocker Cd2+. (ii) A timeplot of the ICa amplitude at 0 mV for the cell illustrated in (i). 
Drugs were applied for the duration of the bars. C) The response of masseter afferents to a high concentration of DAMGO (3 
or 10 µM) is plotted. A reversible inhibition of ICa of 10% or greater was considered a significant response. Note that cells of all 
sizes responded to DAMGO, although only 1 MeV masseter afferent was DAMGO sensitive. All MeV masseter afferents were 
sensitive to baclofen.Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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torphin II (n = 13) inhibited ICa in masseter afferents.
U69-593 inhibited ICa in 1 of 11 unlabeled cells tested (by
57%), deltorphin II did not inhibit ICa in any unlabeled
cells (n = 11). The ORL1 agonist nociceptin (300 nM-1
µM) inhibited ICa in 6/15 (40%) of masseter afferents
(inhibition of ICa was 41 ± 9%) and in 5/12 (42%) of
unlabeled cells (inhibition of ICa was 38 ± 12%). The
GABAB receptor agonist baclofen inhibited ICa in most
ganglion masseter afferents (31/35; 89%, inhibition of ICa
was 26 ± 4%) and unlabeled neurons (15/20; 75%, inhi-
bition of ICa was 24 ± 4%).
We have previously reported that somatostatin receptors
preferentially inhibit ICa in large tooth pulp nociceptors
when compared with small nociceptors [8]. Somatostatin
inhibited ICa in 11/39 labelled masseter afferents and 3/15
unlabelled afferents. Somatostatin inhibited ICa in 5/19
small masseter afferents and 3/7 large masseter afferents
(P = 0.4, χ2). The vast majority of masseter afferents that
did (8/11) or did not (22/28) respond to SRIF also
responded to DAMGO.
DAMGO (3 µM) inhibited ICa in only 1/11 MeV masseter
afferents examined (by 18%). Baclofen (30 µM–100 µM)
inhibited ICa in all MeV masseter afferents examined, by
an average of 33 ± 2% (n = 10, Figure 3B).
Nociceptive Channels
TRPV1
The sensitivity of trigeminal neurons to the TRPV1 agonist
capsaicin (3 µM) was determined by superfusing capsai-
cin onto neurons voltage clamped at -70 mV. Neurons
with reversible capsaicin-induced currents of greater than
500 pA were considered to be sensitive. Many masseter
afferents (65/137; 47%) and most unlabeled neurons
(37/62; 60%) responded to capsaicin, with inward cur-
rents of up to 30 nA. Capsaicin produced inward currents
in cells of all diameters, from 12 µm to 50 µm. Masseter
afferents isolated from the MeV nucleus did not respond
to capsaicin (n = 8).
ATP
The sensitivity of trigeminal neurons to ATP (50 µM) was
determined by a 500 ms application of neurotransmitter
to neurons voltage clamped at -70 mV. Neurons with
reversible ATP-induced currents of greater than 500 pA
were considered to be sensitive. Most masseter afferents
(40/60; 66%) and unlabeled neurons (12/17; 70%) iso-
lated from the TG were sensitive to ATP, with currents of
up to 9500 pA. Masseter afferent responses to by ATP
application were kinetically diverse, with many cells dis-
playing a rapidly activating current that was more than
90% inactivated after 500 ms (19/40; 48%), or a mixture
of rapidly activating and sustained currents (15/40; 38%).
Some cells displayed slowly activating currents that did
not significantly inactivate at the end of the 500 ms pulse
(6/40; 15%). Masseter afferents isolated from the MeV
displayed small sustained currents in response to ATP
application (average amplitude of 150 ± 36 pA, n = 8).
Acid
The sensitivity of masseter afferents to extracellular acidi-
fication was assessed by varying the pH of the external
solution from pH 7.4 to pHs between 7.0 and 5.0. Neu-
rons were voltage clamped at -70 mV and acid solutions
perfused for 5 s. Cells with an inward current of at least
500 pA for a given pH were considered sensitive. Most
masseter afferents (45/70; 64%) displayed robust inward
currents when the extracellular pH was changed from 7.4
to 6.8 (average amplitude 4.9 ± 0.5 nA). Similarly, chang-
ing extracellular pH from 7.4 to 6.8 produced large inward
currents in most unlabeled ganglion afferents (11/19 cells
(58%), average amplitude 6.9 ± 1.4 nA). The inward cur-
rents elicited by changing pH in ganglion masseter affer-
ents could be distinguished by the degree of inactivation
of the current during a pH application to pH 6.0 (Figure
4). The peak inward current in response to a pH step from
7.4 to 6.0 was 11.8 ± 1.5 nA, which declined to 1.2 ± 0.3
nA by 1.5 s (n = 45). In 33/45 (73%) of cells the inward
current at 1.5 s was less than 10% of the peak (average sus-
tained current 3 ± 0.5% of peak), in 12/45 (27%) of cells
the sustained current was greater than 10% of the peak
(average sustained current 24 ± 4% of peak).
In masseter afferents isolated from the MeV nucleus
changing extracellular pH from 7.4 to 6.8 produce an
inward current of only 120 ± 25 pA (n = 11). However,
changing the pH from 7.4 to 6.0 produced inward cur-
rents of 3.5 ± 1 nA in MeV cells, and in 3 cells further
decreasing the pH to 5.0 produced even larger inward cur-
rents (7.5 ± 0.3 nA).
Co-expression of Nociceptive Channels
We were able to examine the co-expression of all 3 of the
putative nociception-related ion channels in 55 TG mas-
seter afferents (Figure 5). Only 4/55 (7%) of neurons
failed to express one of either TRPV1, ASIC or P2X3-like
current (Figure 5a). Conversely, only 3/55 (5%) of cells
expressed all 3 types of current. About half the neurons
(29/55, 53%) expressed at least 2 of the channels while
the remainder (22/55, 40%) expressed only one of the
nociception-related channels. The data for co-expression
of channels is illustrated in Figure 5b. ASIC3-like currents
were the most commonly co-expressed channel in neu-
rons expressing TRPV1 or P2X3-like currents, while no
neurons expressed only TRPV1 and P2X3-like currents.
Discussion
Recordings from muscle afferent fibers have provided a
wealth of information about the response properties ofMolecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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these cells in physiological and pathophysiological situa-
tions, and how these responses are modified by sensory
mediators [9]. However, ion channel activation and the
signal transduction cascades modulating primary afferent
excitability are most directly studied by making electro-
physiological or optical recordings from sensory neuron
Contrasting masseter afferent responses to nociceptive mediators Figure 4
Contrasting masseter afferent responses to nociceptive mediators. In these experiments cells were voltage clamped 
at -70 mV and mediators applied for the duration of the bars. The percentage of all tested cells that responded with currents 
similar to those illustrated is shown below each example trace. A) Perfusion of the TRPV1 agonist capsaicin produced an 
inward current in many (i) trigeminal ganglion masseter afferents but no (ii) MeV masseter afferents. B) Perfusion of ATP pro-
duced inward currents in most (i) trigeminal ganglion masseter afferents and all (ii) MeV masseter afferents. The ATP currents 
in ganglion afferents exhibited a variety of kinetic profiles while those elicited from MeV neurons were uniformly small and 
non-desensitizing. C) Changing the pH of the perfusion solution from 7.4 to various more acidic values produced large inward 
currents in most (i) trigeminal ganglion masseter afferents and all (ii) MeV masseter afferents. Note that MeV neurons required 
greater changes in pH (7.4 to 6.5) to produce detectable inward currents than TG neurons (7.4 to 7.0). Acid-induced currents 
in TG neurons most commonly inactivated completely within about 500 ms, but in about 30% of cells a substantial inward cur-
rent remained at the end of the 2 sec acid perfusion to pH 6.0.Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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cell bodies, and the present study provides some of the
first descriptions of the electrophysiological properties of
isolated sensory neurons innervating muscle. The results
highlight the differences in the molecular signatures of
proprioceptive muscle afferents and other muscle affer-
ents, as well as the differences between muscle afferents
and those which innervate other structures in the head
such as teeth [4,8].
Sensory neuron modality can only be determined in in
vivo or intact ex vivo preparations, thus we cannot assign a
definitive physiological function to the cells in the present
study. However, sensory neurons that detect potentially
noxious stimuli (nociceptors) are thought to preferen-
tially express a number of ion channels not normally
found in other primary afferents. For example, expression
of the TTX-resistant sodium channels NaV1.8 and NaV1.9
has been strongly correlated with a nociceptive sensory
modality in in vivo recordings made from sensory neuron
cell bodies [10,11]. Channels such as the vanilloid recep-
tor TRPV1 are thought to be expressed exclusively by noci-
ceptors because they are normally activated by
demonstrably noxious stimuli and there is a strong corre-
lation between selective pharmacological activation of the
channels and human sensations [7,12]. Other channels
are thought to be associated with nociceptors because
their biophysical properties are sufficient to explain a
response to a noxious stimulus by a subset of sensory neu-
rons. For example, ASIC3 channels are activated by the
modest changes in extracellular calcium and pH that
accompany cardiac ischaemia and are highly expressed in
a subset of cardiac sensory afferents that are presumed to
transmit the pain of angina [5]. The assignment of ion
channels to nociceptive neurons has also been made
based on correlating channel expression with other puta-
tive markers of nociceptors including small soma diame-
ter, expression of substance P, calcitonin gene related
peptide or TRPV1 and expression in sensory neurons
Prevalence and co-expression of putative markers of nociceptive sensory neurons in trigeminal ganglion masseter afferents Figure 5
Prevalence and co-expression of putative markers of nociceptive sensory neurons in trigeminal ganglion mas-
seter afferents. A) The proportion of masseter afferents from TG that expressed substantial (> 500 pA) currents mediated 
by TRPV1-, ASIC3- and P2X3-containing channels is plotted. Virtually all ganglion masseter afferents expressed at least one of 
these channels. B) Co-expression of nociceptive channels in cells expressing (i) TRPV1-like currents, (ii) ASIC-3 like currents 
and (iii) P2X3-like currents. TRPV1 expressing cells often expressed ASIC3-like currents, and P2X3-like currents were only 
found in the cells also expressing ASIC3-like currents. Cells with ASIC3-like currents often expressed either TRPV1 or P2X3-
like currents and occasionally both together. Cells with P2X3-like currents usually expressed ASIC3-like currents but TRPV1-
like currents were only found in the population of these cells also expressing ASIC3-like currents. The numbers of cells in each 
population can be found in the Results.Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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projecting to tissues from which the only conscious sensa-
tion is pain [4].
Almost all the masseter afferents isolated from the TG
expressed significant amounts of at least one of the puta-
tive "nociceptive" ion channels we examined in this study;
capsaicin activated TRPV1 channels, acid activated ASIC-
3-like channels or ATP activated P2X3-like channels. With
the exception of cells expressing TRPV1, a nociceptive
phenotype cannot be reasonably inferred from the expres-
sion of any one channel, however significant numbers of
masseter afferents expressed two or more of the channels
we examined. Almost all cells expressing P2X3-like chan-
nels also expressed ASIC3-like currents and about 25%
also expressed TRPV1; most cells expressing ASIC3-like
currents also expressed either P2X3-like currents or TRPV1,
and more than 50% of the TRPV1 expressing cells also
expressed either P2X3-like currents or ASIC3-like currents.
These data indicate that most TG masseter afferents can
detect a noxious stimulus, but whether this represents
their primary or only function remains unknown. By con-
trast, masseter afferents isolated from the MeV nucleus did
not express TRPV1, P2X3-like or ASIC3-like channels, con-
sistent with their function as purely proprioceptive muscle
spindle afferents [3].
There is considerable evidence that a proportion of mus-
cle afferents can reliably signal stimuli in both the innoc-
uous and noxious range, and the properties of some of
these afferents are consistent with the expression patterns
of the channels in muscle afferents found in the present
study [9]. In particular, afferents that are activated by the
changing metabolic state of muscle (metaboreceptors)
[13] appear to express channels classically associated with
nociceptors, such as TRPV1, but clearly signal non-nox-
ious information as well. Thus, lactic acid stimulation of
muscle afferents in rat produces a classic cardiovascular
pressor response that is sensitive to the ASIC channel
antagonist amiloride but not to the TRPV1 antagonist cap-
sazepine [14]. However, the lactic acid-induced response
is attenuated after pretretament with the potent TRPV1
agonist resiniferatoxin, which desensitizes or destroys
TRPV1-expressing nerves [14]. Further, while capsaicin
produces a pressor response, blocking TRPV1 does not
inhibit a contraction-induced pressor response [15].
Recordings from muscle afferents also show that capsaicin
activates a population of Group III and Group IV affer-
ents, some of which also proton-sensitive [16]. Thus it
seems that a significant proportion of muscle afferents
involved in producing activity-induced cardiovascular
reflexes, perhaps mediated by activation of ASIC channels,
also express TRPV1. Injection of capsaicin into human
masseter muscle is painful [17], so there is no question
that there are TRPV1 expressing afferents in muscle that
transduce noxious stimuli. Our findings that about 50%
of TRPV1 containing masseter afferents also expressed
ASIC channels, and 30% of ASIC expressing afferents
expressed TRPV1 are consistent with these results. There is
no other information about the co-expression of TRPV1,
ASIC and P2X receptors in afferents from the masseter
muscle, although a relatively limited co-expression of
TRPV1 and P2X3 receptors has been reported in gastrocne-
mius-soleus muscle afferents [16].
The ASIC channels in trigeminal masseter afferents
seemed to be largely comprised of homomeric ASIC3
channels or ASIC channel heteromers containing ASIC3.
ASIC3 channels are highly sensitive to changes in extracel-
lular pH and lactate and if activated by a substantial
change in pH they desensitize significantly more rapidly
than other ASIC channels [5,18,19]. The pH 6-induced
currents in most trigeminal ganglion masseter afferents
desensitized more than 90% during the 1.5 s proton
application, while in the remaining neurons the signifi-
cant residual current (> 10% of the peak) suggested the
presence of other ASIC subunits in these cells, probably
ASIC1 [18]. Thus, the majority of ASIC currents observed
in TG ganglion afferents had similar properties to those
found in rat cardiac afferents (18), which are thought to
be ASIC3-mediated. However, in the absence of selective
blockers of ASIC subunits, we cannot definitively assign
the currents we observed to specific ASIC subunits or com-
binations of subunits. MeV masseter afferents exhibited
robust acid-induced currents but these were less sensitive
to changes in extracellular pH and desensitized much
more slowly than ganglion neuron ASIC currents.
In the only previous study of ASIC channel function in
muscle afferents, 50% of sensory neurons labeled from
the gastrocnemius muscle responded to pH 5.0 solution
with robust inward currents [20]. The currents elicited in
30% of the cells were tentatively assigned to ASIC3/
ASIC2b heteromers. The crucial role of ASIC3 channels in
muscle-associated sensory function is underlined by the
main finding of that study, which is that ASIC3 channel
expression is required for the long lasting hyperalgesia
produced by repeated acid injection in muscle [20]. The
currents we observed in the majority of rat masseter affer-
ents differ from those reported in mouse dorsal root gan-
glion neurons [21], primarily due to the lack of a
significant sustained current component at pH 6.0-in our
experiments this component was only 3% of the peak cur-
rent. However, our conclusion that ASIC3 forms an essen-
tial part of masseter afferent ASIC channel complexes, is
similar to that reached by others based on experiments in
mouse DRG neurons from ASIC-null mice [21].Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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Action Potentials and Sodium Channels in Masseter 
Afferents
The action potentials of the MeV masseter afferents were
narrow and lacked an inflection on the downward com-
ponent of the current, consistent with previous recordings
from acutely isolated MeV neurons [22] and MeV neurons
in brain slices [23,24]. The INa recorded from MeV mas-
seter afferents were completely blocked by TTX. These data
are consistent with reports that muscle spindle afferents
do not express detectable NaV1.8 or NaV1.9 immunoreac-
tivity [10,11]. The narrow action potentials of propriocep-
tive afferents are consistent with the very rapid firing rates
that these neurons achieve-exceeding 200 Hz (e.g. [25]).
By contrast, the masseter afferents isolated from the TG
had a wide range of action potential widths and shapes,
and most cells had a significant component of TTX-resist-
ant INa. TTX-resistant INa are subject to acute regulation by
a variety sensory mediators acting via G protein-coupled
or tyrosine kinase-linked receptors, particularly prostag-
landins, bradykinin and nerve growth factor [26]. The
changes in INa availability produced by these mediators
mean that afferents expressing TTX-resistant INa are likely
to be subject to rapid changes in excitability reflecting the
state of the tissue they innervate. Wider action potentials
and greater amounts of TTX-resistant INa are strongly cor-
related with a nociceptive modality, but these properties
vary between afferents of different conduction velocity
classes as well as between afferents of different modality
within a class [27], and one cannot define a neuron as
nociceptive simply on the basis of a action potential dura-
tion or its sensitivity to TTX. Nevertheless, within the TG
masseter afferents, which presumably contain cells with a
nociceptive function, smaller neurons tended to have
wider action potentials. There was no such relationship
apparent within the proprioceptive MeV masseter
afferents.
P2X Receptors
We found a wide variety of ATP-induced currents in TG
masseter afferents, similar to results from other studies in
sensory neurons [28-30]. Messenger RNA and receptor-
like immunoreactivity for 6 of the 7 cloned subtypes of
P2X receptor are found in the trigeminal ganglion [31,32]
and the currents we recorded are likely to be comprised of
a mixture of homo- and heteromeric P2X receptor chan-
nels. Although attempting to define the P2X subunits
responsible for the variety of ATP currents was beyond the
scope of this study (but see [28]) we attributed the rapidly
desensitizing ATP current observed in some masseter
afferents to P2X3 receptor activation. Rapidly desensitiz-
ing ATP currents in sensory neurons have been reported to
depend on the presence of the P2X3 gene or have been
identified pharmacologically as P2X3 receptors [33-35]
and although the kinetically similar P2X1 receptor has
been shown to be present in sensory neurons by immuno-
histochemical methods, there is little electrophysiological
evidence for currents mediated by P2X1 receptors in rat or
mouse sensory neurons [4,29].
P2X3 subunits make a major contribution to the ATP cur-
rents in trigeminal neurons projecting to the tooth pulp,
both as P2X3 receptor homomers and putative P2X2/P2X3
heteromers [4]. Relatively fewer masseter afferents express
P2X3-like immunoreactivity [36]. In the present study we
observed rapidly desensitizing ATP currents either alone
or in combination with other P2X currents in about 55%
of TG masseter afferents, which is similar to the propor-
tion of tooth pulp nociceptors which displayed fast ATP
currents (44%, [4]). P2X3-like immunoreactivity has been
reported in about 25% of masseter afferents [36], which is
a considerably smaller proportion than suggested by the
present report. These differing results may reflect differing
sensitivities of immunohistochemistry and electrophysi-
ology, they may be due to the presence of some P2X1-con-
taining currents in masseter afferents or perhaps arise
from the short time the isolated neurons spend in culture.
30 – 40% of tooth pulp afferents can be labeled with P2X3
antiserum [4,37] but it is interesting to note that more
than 50% of tooth pulp afferents challenged with ATP
also displayed persistent currents. This indicates that
while P2X3-containing ATP receptors are found in many
putative nociceptors, they are not the only P2X subunits
that may detect noxious stimuli signalled by ATP.
Opioid Modulation of Calcium Channels
The relatively high µ-opioid receptor sensitivity of jaw
muscle afferents is similar to that reported in afferents
projecting to hindlimb muscles, where about 75% of cells
were sensitive to DAMGO [38]. The apparently high
sensitivity of muscle afferent ICa to µ-opioid agonists con-
trasts with the reported low frequency of µ-opioid agonist
modulation of ICa in skin and colonic afferents (approxi-
mately 10%, [39]). The relative insensitivity of MeV ICa to
DAMGO (1 of 11 cells responding) is consistent with the
extremely low mRNA abundance in these cells (2 of 72,
[40]). The modulation of ICa in MeV neurons by the
GABAB receptor agonist baclofen is in contrast to the lack
of affect of baclofen on the membrane properties of MeV
neurons in slices [41].
Interestingly, the µ-opioid receptor sensitivity of masseter
muscle afferents differs markedly from that reported for
the "purely nociceptive" afferents from tooth pulp [8,40].
DAMGO inhibited ICa in more masseter afferents than
tooth pulp afferents, regardless of cell size (80% versus
42% respectively [40]), and most strikingly, DAMGO was
equally effective in small and large masseter afferents
(85% and 82% of cells inhibited respectively). By con-
trast, DAMGO inhibited ICa in only 30% of large tooth
pulp afferents [8]. As 30% of large masseter afferents hadMolecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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substantial capsaicin currents (> 500 pA), indicating that
these cells are likely to be nociceptors, our data suggest
that µ-opioid receptors may be differentially expressed in
distinct populations of nociceptors projecting to different
tissues in the head, i.e. preferentially expressed in muscle
nociceptors versus tooth pulp nociceptors. These data
suggest that opioid analgesics may be better at relieving
some types of head pain than others, and further that the
endogenous opioid analgesic systems of the periphery
may display differential effectiveness against nociceptive
stimuli arising from distinct structures. The apparently
high expression of opioid receptors in TG masseter affer-
ents also suggests that these receptors may have functions
in muscle physiology other than simple inhibition of
nociception.
Conclusion
This study demonstrates that most masseter muscle affer-
ents isolated from the trigeminal ganglion express one or
more ion channels associated with detecting noxious
stimuli, while masseter muscle proprioceptive afferents
isolated from the MeV a different array of ion channels
consistent with their non-nociceptive phenotype. It
remains to be seen whether this profile is typical of sen-
sory innervation of skeletal muscle, and whether the phe-
notypes described in this study undergo significant
changes in chronic pathologies of the masseter muscle or
associated nerves.
Methods
Cell labelling
All experiments were carried out using protocols approved
by the OHSU Institutional Animal Care and Use Commit-
tee. Masseter afferents were labeled as outlined in detail in
[42]. Briefly, male Sprague-Dawley rats between 5–8
weeks old were anesthetized with a s.c. injection of "rat
cocktail" consisting of ketamine (55 mg kg -1), xylazine
(5.5 mg kg -1 and acepromazine (1.1 mg kg -1). A small
incision was made in skin overlying each masseter muscle
and 5 × 1 µl injections of DiI (5% in DMSO) were made
into each muscle with a Hamilton 10 µl syringe. The
wound was closed with cyanoacrylate glue and the ani-
mals returned to their cages. Sensory neurons were iso-
lated 2 weeks after surgery.
Cell Isolation
Cells were isolated from trigeminal ganglia essentially as
described in [42]. Briefly, rats were anaesthetized with
halothane (4%), and killed by decapitation. The trigemi-
nal ganglia were removed and placed in cold Ca2+/Mg2+-
Free Hanks Solution (CMF Hanks). Ganglia were cut up
with iridectomy scissors and incubated at 35°C for 20
minutes in CMF Hanks plus papain (20 U ml-1), followed
by 20 minutes in CMF Hanks plus dispase (4 mg ml-1) and
collagenase (3 mg ml-1). The enzyme incubation was
stopped with F-12 media supplemented with 10% fetal
bovine serum (FBS), 50 U/ml penicillin/streptomycin,
and the cells were released by gentle trituration through
decreasing bore Pasteur pipettes with fire-polished tips.
Cells were plated on plastic culture dishes precoated with
poly-D-lysine and laminin. After the cells had settled they
were cultured in a humidified chamber at room tempera-
ture in Leibovitz's L-15 medium supplemented with 10%
FBS, 50 ng ml-1 NGF, 5 mM glucose, 5 mM NaHEPES and
50 U ml-1 penicillin/streptomycin.
Cells were isolated from the MeV nucleus by a modifica-
tion of the methods outlined in [42]. Briefly, rats were
anaesthetized with halothane and killed by a blow to the
chest. The brain was rapidly removed and a block contain-
ing the brainstem immersed in ice cold artificial cerebros-
pinal fluid of composition (mM): NaCl 126, KCl 2.5,
NaH2PO4 1.4, MgCl2 1.2, CaCl2 2.4, glucose 11, NaHCO3
25. Slices of the brainstem (400 µM) containing the MeV
region were made with a Leica vibratome and the region
containing the MeV cells subdissected with fine needles.
The tissue chunks were placed in modified HBS (Solution
1 containing 10 mM MgCl2, 2 mM CaCl2) containing
papain, 20 U ml-1 and incubated for 3–5 minutes at 37°C.
The enzyme incubation was stopped with F-12 media sup-
plemented with 10% FBS, 25 ng ml -1 NT-3 and 50 U/ml
penicillin/streptomycin, and the cells were released by
gentle trituration through decreasing bore Pasteur pipettes
with fire-polished tips. The cells were plated onto culture
plates with confluent, quiescent glia and cultured over-
night at 37°C.
Electrophysiological Recording
Ionic currents from trigeminal neurons were recorded in
the whole-cell configuration of the patch-clamp method
[43] at room temperature (22–24°C), as described in
[44]. The solutions used to record different types of cur-
rent are listed in Table 1. Dishes were continually perfused
with HEPES buffered saline (HBS, Solution 1). Calcium
channel currents (ICa), were recorded in Solution 2,
recordings of sodium channel currents (INa) were made in
Solution 3. Recordings of ICa and INa were made with fire
polished borosilicate pipettes (A-M Systems #603500,
Carlsborg WA) filled with (in mM): CsCl 120, MgATP 5,
NaCl 5, Na2GTP 0.3, EGTA 10, CaCl2 2 and HEPES 20, pH
7.3, resistance approximately 2 MΩ. In the cells where ICa
and  INa  were recorded, capsaicin currents were also
recorded with the above internal solution. Action poten-
tials were recorded in Solution 4, with an internal solu-
tion that consisted of (mM): K methanesulphonate 115,
KCl 5, NaCl, 8, MgCl2, 1, MOPS 10, MgATP 2, Na2GTP
0.3, BAPTA-K4 10, pH 7.0. In these recordings thin walled
7052 type glass (Garner Glass Company, Claremont CA)
was used.Molecular Pain 2005, 1:31 http://www.molecularpain.com/content/1/1/31
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Recordings were made using either an Axopatch 1D
amplifier (Axon Instruments, Union City, CA, USA) or a
HEKA EPC 9 amplifier using Pulse acquisition and analy-
sis software (HEKA). Currents were filtered at 3–5 kHz,
sampled at 20–100 KHz, and recorded on hard disk for
later analysis. Series resistance ranged from 2–7 MOhm
and was compensated by 80% in all experiments. An
approximate value of whole cell capacitance was deter-
mined by nulling the amplifier capacitance compensation
circuit (Axoptach 1D) or automatically by EPC 9. Leak
current was subtracted on line using a P/8 protocol. Cells
were exposed to drugs via a series of flow pipes positioned
about 200 µM from the cells. Fast application of ATP, cap-
saicin and acid were made with valve controlled sewer
pipes.
Data analysis
Significant differences between means were tested using
unpaired, two tailed Students t-test as noted. All data are
expressed as mean ± S.E.mean unless otherwise indicated.
Drugs and Chemicals
DAMGO ([Tyr-D-Ala-Gly-MePhe-Gly-ol]enkephalin), U-
69593 ((+)-(5-, 7-, 8-)-N-methyl-N-[7-(1-pyrrolidinyl)-1-
oxaspiro[4.5]dec-8-yl]benzeneacetamide), deltorphin II,
capsaicin, laminin, polylysine were from Sigma. Buffer
salts were from Sigma. F-12, L-15 and fetal bovine serum
were from GIBCO. Tetrodotoxin and human NT-3 were
from Alomone Laboratories. NGF (mouse 2.5 S) was from
either Upstate or Sigma. Papain and collagenase were
from Worthington Biochemical Corporation (Freehold,
NJ, USA), dispase was from Roche Applied Sciences.
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